Fig. 8: LRRK2 kinase inhibitor treatment restored LRRK2 G2019S induced mtDNA damage to basal healthy control levels.
From: G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
a PD patient-derived heterozygous G2019S LRRK2 carriers and age-matched healthy controls LCLs treated with DMSO, 10 nM, or 100 nM MLi-2 or (c) EB-42168 for 2 h and analyzed for mtDNA damage. b, d mtDNA copy number was unaltered by these treatments. Data are presented as mean ± SEM. (*p < 0.05 determined by one-way ANOVA).
